Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Magnevist · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Magnevist (SH L 451A) | DRUG | Magnevist at a dose of 0.1 mmol/kg |
| Magnevist (Gadopentetate dimeglumine, BAY86-4882) | DRUG | One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight |
Inclusion Criteria: * Patients who are confirmed to have 1-5 metastatic brain tumor by the latest contrast-enhanced cerebral CT or contrast-enhanced cerebral MRI, and the lesion(s) have not been treated by surgery or by stereotactic radiosurgery. Exclusion Criteria: * Patients who are scheduled t...
Magnevist is a small molecule contrast agent studied for use in myocardial infarction and brain neoplasms. Clinical trials have evaluated it for depicting delayed enhancement in patients with documented myocardial infarction and for intra-individual dose comparison in patients with brain metastasis.
Magnevist is developed by Bayer AG, which trades under the ticker BAYRY. The company has sponsored clinical trials of the drug in the United States, Argentina, and Japan.
Magnevist is in Phase 3 clinical development. One completed Phase 3 trial evaluated the drug in patients with brain neoplasms, and a completed Phase 2 trial studied it in myocardial infarction. It remains investigational and is not approved.
Magnevist has one completed Phase 2 trial, NCT00310544, which enrolled 73 participants with myocardial infarction in the United States and Argentina. A completed Phase 3 trial, NCT00681551, enrolled 45 participants with brain neoplasms in Japan.
Yes, Magnevist is also known as SH L 451A. The Phase 3 trial in brain metastasis is titled 'Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis.'